scholarly journals “Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial”

2020 ◽  
Vol 52 (7) ◽  
pp. 730-733 ◽  
Author(s):  
Julien Taïeb ◽  
Léonor Benhaim ◽  
Pierre Laurent Puig ◽  
Karine Le Malicot ◽  
Jean François Emile ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Treatment ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

Mismatch repair status predicts survival after adjuvant treatment in stage II colon cancer patients

2019 ◽  
Vol 121 (2) ◽  
pp. 392-401 ◽  
Author(s):  
I. Gkekas ◽  
J. Novotny ◽  
P. Fabian ◽  
R. Nemecek ◽  
R. Palmqvist ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Mismatch Repair ◽  
Adjuvant Treatment ◽  
Stage Ii ◽  
Mismatch Repair Status ◽  
Stage Ii Colon Cancer

Effect of Oncotype DX colon cancer test results on treatment recommendations in patients with stage II colon cancer: Preliminary results.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 398-398
Author(s):  
Thomas H. Cartwright ◽  
Calvin Chao ◽  
Margarita Lopatin ◽  
Tanya GK Bentley ◽  
Michael Samuel Broder ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Recurrence Score ◽  
Treatment Recommendations ◽  
Oncotype Dx ◽  
Stage Ii ◽  
Medical Oncologists ◽  
Stage Ii Colon Cancer ◽  
The Impact

398 Background: The Oncotype DX Colon Cancer Recurrence Score (RS) has been clinically validated as an independent predictor of individual recurrence risk in stage II colon cancer patients following surgery. As a result, physicians have been ordering the Oncotype DX assay for stage II colon cancer patients since January 2010, yet no data exist on the assay’s impact on adjuvant treatment planning in practice. We performed a survey to characterize the impact of the assay on adjuvant treatment recommendations in stage II colon cancer. Methods: U.S. medical oncologists (N=277) who ordered Oncotype DX for ≥3 patients with stage II colon cancer were contacted and asked to complete a web-based survey regarding the single most recent stage II colon cancer patient for whom the assay was ordered. The survey was developed through cognitive interviews with four medical oncologists, and the protocol was institutional review board approved. Results: As a planned preliminary analysis, we analyzed surveys from 92 eligible physicians. Physicians were more often in community (85%) than academic or other practices, and had a median of 14.5 years (range, 2-40) of practice experience. The median patient age was 62 years (range, 34–81). 84% of patients had T3 disease. Patients had ≤8, 9-11 and ≥12 nodes examined 2%, 14% and 84% of the time and 36% had comorbidities. Of the 60 patients tested for MMR/MSI, 9 (15%) were MMR-D or MSI-high and 37 (62%) were MMR-P or MSI-low; 14 (23%) unknown. Median RS was 20 (range, 1-77). Before obtaining the RS, chemotherapy was planned in 38 (41%) patients, observation in 35 (38%), and there was no recommendation in 19 (21%). For the 73 patients with pre-assay recommendations, recommended treatment changed after obtaining the RS for 23 patients (32%), including changes from chemotherapy to observation and vice-versa. Conclusions: These preliminary findings indicate that for stage II colon cancer patients, treatment recommendations were changed by RS results approximately one-third of the time. Final results will be reported to include accrual through December 2011.

scholarly journals Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581

2011 ◽  
Vol 29 (23) ◽  
pp. 3146-3152 ◽  
Author(s):  
Donna Niedzwiecki ◽  
Monica M. Bertagnolli ◽  
Robert S. Warren ◽  
Carolyn C. Compton ◽  
Nancy E. Kemeny ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Natural History ◽  
Adjuvant Treatment ◽  
Stage Ii ◽  
Survival Outcomes ◽  
History Of ◽  
Resected Stage ◽  
Stage Ii Colon Cancer ◽  
Disease Specific

Purpose We conducted a randomized trial comparing adjuvant treatment with edrecolomab versus observation in patients with resected, low-risk, stage II colon cancer. This study also prospectively studied patient- and tumor-specific markers of treatment outcome. Patients and Methods After surgical resection, patients with stage II colon cancer were randomly assigned to either five infusions of edrecolomab at 28-day intervals or observation without adjuvant therapy. Results Final accrual included 1,738 patients; 865 patients received edrecolomab, and 873 patients were observed without adjuvant treatment. Median follow-up time was 7.9 years. There were no significant outcome differences between study arms (overall survival [OS], P = .71; disease-free survival, P = .64). The combined 5-year all-cause OS was 0.86 (95% CI, 0.84 to 0.88), and the combined 5-year disease-specific OS was 0.93 (95% CI, 0.91 to 0.94). The relationships between demographic and histopathologic factors and survival differed for all-cause and disease-specific survival outcomes, but no combined prognostic factor model was found to adequately classify patients at higher risk of recurrence or death as a result of colon cancer. Conclusion Edrecolomab did not prolong survival. Consequently, this large study with a long duration of follow-up provided unique data concerning the natural history of resected stage II colon cancer. Prognostic factors identified in previous retrospective and pooled analyses were associated with survival outcomes in this stage II patient cohort. Results from ongoing molecular marker studies may enhance our ability to determine the risk profile of these patients.

scholarly journals Current Issues in Adjuvant Treatment of Stage II Colon Cancer

2006 ◽  
Vol 13 (6) ◽  
pp. 887-898 ◽  
Author(s):  
Thierry André ◽  
Daniel Sargent ◽  
Josep Tabernero ◽  
Michael O’Connell ◽  
Marc Buyse ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Treatment ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data

2020 ◽  
Vol 146 (11) ◽  
pp. 2968-2978 ◽  
Author(s):  
Gabrielle Jongeneel ◽  
Thomas Klausch ◽  
Felice N. Erning ◽  
Geraldine R. Vink ◽  
Miriam Koopman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Colon Cancer ◽  
Randomized Clinical Trial ◽  
Adjuvant Treatment ◽  
Real World ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Stage Ii ◽  
Real World Data ◽  
Stage Ii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document